Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Post-Market Trading 06-27 17:23:24 EDT

27.91

+0.30

+1.09%

盘后27.91

+0.000.00%

16:20 EDT

High28.06	Low27.38	Vol438.30K
Open27.84	D1 Closing27.61	Amplitude2.44%
Mkt Cap1.30B	Tradable Cap1.29B	Total Shares46.55M
T/O12.20M	T/O Rate0.95%	Tradable Shares46.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":27.91,"timestamp":1719518400000,"preClose":27.61,"halted":0,"volume":438297,"hourTrading":{"tag":"盘后","latestPrice":27.91,"preClose":27.91,"latestTime":"16:20 EDT","volume":18292,"amount":510529.72000000003,"timestamp":1719519600498},"delay":0,"floatShares":46057464,"shares":46546148,"eps":1.416418,"marketStatus":"Post-Market Trading","change":0.3,"latestTime":"06-27 17:23:24 EDT","open":27.84,"high":28.055,"low":27.38,"amount":12198821.146796,"amplitude":0.024448,"askPrice":28.45,"askSize":59,"bidPrice":27.22,"bidSize":150,"shortable":3,"etf":0,"ttmEps":1.416418,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1719532800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":27.61,"preHourTrading":{"tag":"盘前","latestPrice":27.61,"preClose":27.61,"latestTime":"08:51 EDT","volume":758,"amount":20963.029696,"timestamp":1719492687938},"postHourTrading":{"tag":"盘后","latestPrice":27.91,"preClose":27.91,"latestTime":"16:20 EDT","volume":18292,"amount":510529.72000000003,"timestamp":1719519600498},"volumeRatio":0.420367,"impliedVol":0.6944,"impliedVolPercentile":0.7897},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2444210608","title":"Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2444210608","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444210608?lang=en_us&edition=fundamental","pubTime":"2024-06-20 22:09","pubTimestamp":1718892579,"startTime":"0","endTime":"0","summary":"With its stock down 7.9% over the past month, it is easy to disregard Pacira BioSciences . However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. In this article, we decided to focus on Pacira BioSciences'  ROE.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.On the face of it, Pacira BioSciences' ROE is not much to talk about. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 14%. As a result, Pacira BioSciences' flat net income growth over the past five years doesn't come as a surprise given its lower ROE.Pacira BioSciences doesn't pay any regular dividends, meaning that potentially all of its profits are being ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/declining-stock-decent-financials-market-140939115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","SQQQ","BK4585","BK4007","LU2095319765.USD","LU2210150020.SGD","NDAQ",".IXIC","QQQ","PCRX","BK4112","TQQQ","MNQmain","QID","LU2210149790.SGD","NQmain","PSQ","BK4588"],"gpt_icon":0},{"id":"2443624870","title":"Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Pacira Pharmaceuticals (PCRX) and Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2443624870","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443624870?lang=en_us&edition=fundamental","pubTime":"2024-06-14 20:11","pubTimestamp":1718367097,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX – Research Report), Pacira...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viking-therapeutics-vktx-pacira-pharmaceuticals-pcrx-and-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viking-therapeutics-vktx-pacira-pharmaceuticals-pcrx-and-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4578","BK4585","PCRX","LU0234570918.USD","BK4583","BK4568","IE00BSNM7G36.USD","BK4137","IE00BKVL7J92.USD","LU0058720904.USD","LU1571399168.USD","VKTX","BK4566","LU1839511570.USD","LU2468319806.SGD","BK4532","BK4139","BK4588","LU0109394709.USD","BK4007","LU1585245621.USD","LU0889565916.HKD","LU0289739699.SGD","GILD","LU0320765992.SGD","LU1066051498.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","BK4550","LU1066053197.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2443619411","title":"Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2443619411","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443619411?lang=en_us&edition=fundamental","pubTime":"2024-06-14 14:41","pubTimestamp":1718347295,"startTime":"0","endTime":"0","summary":"Jonathan Slonin, Chief Medical Officer of Pacira BioSciences Inc , executed a sale of 5,012 shares of the company on June 11, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 98,869.475 shares of the company.GuruFocus has detected 3 Warning Sign with PCRX.Pacira BioSciences Inc  is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company primarily engages in the development of non-opioid products for the management of post-surgical pain.Over the past year, the insider transaction history at Pacira BioSciences Inc shows a total of 10 insider sells and no insider buys. This recent transaction by Jonathan Slonin aligns with the ongoing trend of insider sales within the company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9Sxh.XY_729rGZZBPFtTA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9f2b028b6111437edfef3f1de56aa666","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9Sxh.XY_729rGZZBPFtTA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9f2b028b6111437edfef3f1de56aa666"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-sale-chief-medical-officer-064135523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2443654297","title":"Pacira Pharmaceuticals Announces Board Changes and Shareholder Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2443654297","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443654297?lang=en_us&edition=fundamental","pubTime":"2024-06-14 05:59","pubTimestamp":1718315953,"startTime":"0","endTime":"0","summary":"An announcement from Pacira Pharmaceuticals (PCRX) is now available. Gary Pace announced his plan to retire from the Board of Directors of Pacira B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pacira-pharmaceuticals-announces-board-changes-and-shareholder-approvals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pacira-pharmaceuticals-announces-board-changes-and-shareholder-approvals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2439695643","title":"Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2439695643","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439695643?lang=en_us&edition=fundamental","pubTime":"2024-05-30 20:00","pubTimestamp":1717070400,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/30/2890680/0/en/Pacira-BioSciences-to-Participate-in-Fireside-Chat-at-the-2024-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","HCSG","BK4007","BK4137"],"gpt_icon":0},{"id":"2435266442","title":"enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2435266442","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435266442?lang=en_us&edition=fundamental","pubTime":"2024-05-16 04:05","pubTimestamp":1715803500,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, May 15, 2024----enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer , today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company’s 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene’s Board is now comprised of seven members including Richard Glickman , Gerald Brunk, Jasper Bos, and Jason Hanson.\"We are pleased to welcome Paul and Wouter to our Board of Directors. Their breadth of biopharma industry experience across research, corporate management and finance equips them well to serve as Board members of enGene, particularly as we look to the potential expansion of our pipeline across additional urological indications and move towards our planned ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ffjMc5qeVkRuu9e1gU8Bog--~B/aD05NTc7dz0zMTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9551ceba7d89b2cbe89336acd6391e8c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ffjMc5qeVkRuu9e1gU8Bog--~B/aD05NTc7dz0zMTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9551ceba7d89b2cbe89336acd6391e8c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-announces-election-paul-hastings-200500599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENGNW","QLD","BK4585","BK4007","NAMS","BK4539","VECT","QID","BK4588","MNQmain","BIO","QQQ","NKTX","ENGN","PSQ","BK4135","NQmain","PCRX",".IXIC","BK4121","BK4505","TQQQ","BCG","SQQQ","BK4139"],"gpt_icon":0},{"id":"2435669450","title":"Top Stock Reports for Broadcom, Merck & Airbnb","url":"https://stock-news.laohu8.com/highlight/detail?id=2435669450","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435669450?lang=en_us&edition=fundamental","pubTime":"2024-05-16 01:11","pubTimestamp":1715793060,"startTime":"0","endTime":"0","summary":"Airbnb shares have gained +7.7% over the year-to-date period against the Zacks Internet - Content industry’s gain of +9.8%. The company’s first-quarter 2024 results benefited from continuous improvements in Nights and Experiences Booked, owing to growing travel demand and the timing of the Easter holiday.This, in turn, enabled Airbnb to witness a positive trend in its Gross Booking Value. Growing gross nights booked, owing to the solid momentum across non-urban areas and increased demand for urban and cross-border travel, remained positive. A modest increase in Average Daily Rate was a plus. Strong momentum in Airbnb app downloads is a tailwind.However, greater volatility in travel demand due","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-stock-reports-broadcom-merck-171100771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0417517546.SGD","KSS","SONO","BK4585","LU2023250843.SGD","IE00BMPRXN33.USD","ENB","LU0689472784.USD","IE00BFTCPJ56.SGD","LU0056508442.USD","IE00B2B36J28.USD","OKE","MRK","PCRX","LU0070302665.USD","AVGO","AVGOP","LU0820561818.USD","PCG","XRX","BK4554","LU1244550577.SGD","BK4534","LU1162221912.USD","SG9999013999.USD","BK4006","BK4141","LU1242518931.SGD","BK4127","LSTR","BK4547","BK4142","RS","LU0979878070.USD","BK4535","LU0985320562.USD","LU2023250504.SGD","LU2106854487.HKD","LU0957808578.USD","HUBS","AMN","ABNB","IE00B894F039.SGD","LU0198837287.USD","SLF","IE00BWXC8680.SGD","LU1548497426.USD","RJF","BK4533","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2434610858","title":"Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2434610858","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434610858?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:44","pubTimestamp":1715341493,"startTime":"0","endTime":"0","summary":"Investors in Pacira BioSciences, Inc.  had a good week, as its shares rose 9.3% to close at US$29.86 following the release of its quarterly results. It was not a great result overall. While revenues of US$167m were in line with analyst predictions, earnings were less than expected, missing statutory estimates by 17% to hit US$0.19 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.NasdaqGS:PCRX Earnings and Revenue Growth May 10th 2024. The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-miss-pacira-biosciences-inc-114453668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX"],"gpt_icon":0},{"id":"2434374618","title":"Pacira BioSciences announces pricing of convertible senior notes due 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2434374618","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434374618?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:17","pubTimestamp":1715339868,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (NASDAQ:PCRX) Friday announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 in a private placement to qualified institutional buyers","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104469-pacira-biosciences-announces-pricing-of-convertible-senior-notes-due-2029","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2434832803","title":"BRIEF-Pacira Biosciences, Announces Pricing Of $250.0 Million Aggregate Principal Amount Of 2.125% Convertible Senior Notes Due 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2434832803","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434832803?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:07","pubTimestamp":1715339242,"startTime":"0","endTime":"0","summary":"May 10  - Pacira Biosciences Inc   :   * PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.125% CONVERTIBLE SENIOR NOTES DUE 2029   * PACIRA CONVERTIBLE SENIOR NOTES MATURITY SET FOR MAY 15, 2029Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4162","LU1989772840.SGD","BK4534","PFG","PCRX","BK4588","BK4007","LU1989772923.USD","BK4585","BK4566"],"gpt_icon":0},{"id":"2434709976","title":"BRIEF-Pacira Biosciences, Inc. Announces Proposed Offering Of $250.0 Million Aggregate Principal Amount Of Convertible Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2434709976","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434709976?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:55","pubTimestamp":1715201743,"startTime":"0","endTime":"0","summary":"May 8 (Reuters) - Pacira Biosciences Inc   :   * PACIRA BIOSCIENCES, INC. ANNOUNCES PROPOSED OFFERING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTESSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","BK4566","BK4585","BK4007","PFG","PCRX","BK4534","LU1989772840.SGD","BK4162","BK4588"],"gpt_icon":0},{"id":"2434705452","title":"Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2434705452","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434705452?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:05","pubTimestamp":1715198700,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., May 08, 2024  -- Pacira BioSciences, Inc.  today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029  in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended . Pacira also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.In connection with the pricing of the notes, Pacira expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions . The capped call transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of sha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H0qAGhFTMrdvcpmPFC8QsQ--~B/aD0xOTc7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e57f08640ce0bb89697b60bd66dca2cf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H0qAGhFTMrdvcpmPFC8QsQ--~B/aD0xOTc7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e57f08640ce0bb89697b60bd66dca2cf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-inc-announces-proposed-200500384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989772840.SGD","PFG","BK4566","BK4162","BK4534","BK4588","BK4585","BK4007","PCRX","LU1989772923.USD"],"gpt_icon":0},{"id":"2434711527","title":"Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2434711527","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434711527?lang=en_us&edition=fundamental","pubTime":"2024-05-08 23:35","pubTimestamp":1715182500,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc.PCRX reported first-quarter 2024 adjusted earnings of 62 cents per share, which missed the Zacks Consensus Estimate of 64 cents. The company had reported adjusted earnings of 49 cents per share in the year-ago quarter.Total revenues amounted to $167.1 million, which increased 4% year over year and surpassed the Zacks Consensus Estimate of $165 million.Pacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from the sales of its three marketed drugs: Exparel, Zilretta and iovera.Exparel’s net product sales were $132.4 million, which rose 2% from the year-ago quarter and missed both the Zacks Consensus Estimate of $134.6 million and our estimate of $133.3 million. Revenues generated from Exparel sales were negatively impacted by contracted discounts and vial mix, which led to the low sales growth rate in the reported quarter.The company anticipates adjusted R&D expenses between $70 million and $80 million,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-pcrx-q1-earnings-miss-153500113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","ANIP","LGND","ANVS"],"gpt_icon":0},{"id":"2433727855","title":"Pacira Biosciences Up Nearly 12%, On Track for Largest Percent Increase Since November 2020 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2433727855","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433727855?lang=en_us&edition=fundamental","pubTime":"2024-05-08 22:32","pubTimestamp":1715178720,"startTime":"0","endTime":"0","summary":"Pacira Biosciences, Inc.  is currently at $29.64, up $3.14 or 11.83%. --Would be highest close since March 20, 2024, when it closed at $30.02. --On pace for largest percent increase since Nov. 9, 2020, when it rose 13.73%. --Currently up two consecutive days; up 11.87% over this period. --Down 75.14% from its all-time closing high of $119.27 on Feb. 25, 2015. --Down 30.88% from 52 weeks ago , when it closed at $42.89. --Down 30.88% from its 52-week closing high of $42.89 on May 10, 2023. --Up 16.25% from its 52-week closing low of $25.50 on April 25, 2024. --Traded as high as $30.43; highest intraday level since March 13, 2024, when it hit $30.95. --Up 14.79% at today's intraday high; largest intraday percent increase since Nov. 9, 2020, when it rose as much as 15.73%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2433729983","title":"Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2433729983","media":"Insider Monkey","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433729983?lang=en_us&edition=fundamental","pubTime":"2024-05-08 21:33","pubTimestamp":1715175238,"startTime":"0","endTime":"0","summary":"Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.62 EPS, expectations were $0.64. PCRX isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Thank you for standing by. My name is Hermione and I will be your conference operator today. At this time, I would like to welcome everyone to Q1 2024 Pacira BioScience Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question-and-answer session. po [Operator instructions] I would now like to turn the call over to Susan Mesco, Head of Investor Relations. Please go ahead.I'll start with lower extremity nerve block, where we're seeing positive market receptivity across all sites of care, delivering four days of opioid-sparing pain control with a single 10 ml EXPAREL dose is an attractive value proposition to the anesthesia and surgical community; for knee, foot and ankle surgeries. Physici","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0Sfj6XpZb2SS0q0leCTepw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac4caa9aa7e79bd6e4c34742e25c3929","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0Sfj6XpZb2SS0q0leCTepw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ac4caa9aa7e79bd6e4c34742e25c3929"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-inc-nasdaq-pcrx-133358337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2433744920","title":"Piper Sandler Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433744920","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433744920?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:10","pubTimestamp":1715166659,"startTime":"0","endTime":"0","summary":"In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-pacira-pharmaceuticals-pcrx-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-pacira-pharmaceuticals-pcrx-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX"],"gpt_icon":0},{"id":"2433749097","title":"Pacira BioSciences Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2433749097","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433749097?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:48","pubTimestamp":1715165280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2024 06:48 ET (10:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2433194487","title":"Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2433194487","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433194487?lang=en_us&edition=fundamental","pubTime":"2024-05-08 15:47","pubTimestamp":1715154449,"startTime":"0","endTime":"0","summary":"Q1 EXPAREL Sales: Increased to $132.4 million from $130.4 million in Q1 2023.Q1 ZILRETTA Sales: Rose to $25.8 million from $24.3 million in Q1 2023.Q1 iovera Sales: Grew to $5 million from $4 million in Q1 2023.Consolidated Gross Margin: Reported at 72% for Q1.Non-GAAP R&D Expense: Increased to $16.4 million from $15.3 million in Q1 2023.Non-GAAP SG&A Expense: Rose to $63.8 million from $62.5 million in Q1 2023.Interest Expense: Improved to $3.3 million from $9.6 million in Q1 2023.Adjusted EBITDA: Reported at $44.6 million for Q1.2024 Revenue Guidance: Projected at $680 million to $705 million.2024 Non-GAAP Gross Margin Guidance: Expected to be between 74% and 76%.2024 Non-GAAP R&D Expense Guidance: Anticipated to be between $70 million and $80 million.2024 Non-GAAP SG&A Expense Guidance: Forecasted to be between $245 million and $265 million.2024 Stock-Based Compensation Guidance: Estimated to be between $50 million and $55 million.Stock Repurchase Plan: Announced a $150 million plan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-inc-pcrx-q1-074729102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX"],"gpt_icon":0},{"id":"2433755204","title":"Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2433755204","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433755204?lang=en_us&edition=fundamental","pubTime":"2024-05-08 06:03","pubTimestamp":1715119430,"startTime":"0","endTime":"0","summary":"Total Revenue: Reached $167.1 million in Q1 2024, up from $160.3 million in Q1 2023, exceeding estimates of $165.35 million.Net Income: Reported at $9.0 million, or $0.19 per share, significantly below the estimated $0.19 per share.Earnings Per Share : Basic and diluted EPS stood at $0.19, falling short of the estimated $0.62.EXPAREL Net Product Sales: Totaled $132.4 million, showing a slight increase from $130.4 million in the previous year.Operating Expenses: Decreased to $153.9 million from $163.4 million year-over-year, contributing to improved operational efficiency.Cash Flow: Cash provided by operations was $49.1 million, a substantial increase from $19.1 million in Q1 2023.Share Repurchase Program: Announced a new $150 million share repurchase program, highlighting confidence in financial stability and future growth prospects.On May 7, 2024, Pacira BioSciences Inc  released its 8-K filing, announcing its financial results for the first quarter of 2024. The company, a leader in n","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/L6Cd7CqgYWsY6.H5MK06bA--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/71c9c1dd1d05b53ab279f9ccd6cc17b1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/L6Cd7CqgYWsY6.H5MK06bA--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/71c9c1dd1d05b53ab279f9ccd6cc17b1"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-reports-q1-2024-220350908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0551},{"period":"6month","weight":-0.1817},{"period":"1year","weight":-0.3054},{"period":"ytd","weight":-0.1817}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.1477},{"period":"1year","weight":0.2507},{"period":"ytd","weight":0.1477}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.042499},{"month":2,"riseRate":0.692308,"avgChangeRate":0.029842},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.007802},{"month":4,"riseRate":0.571429,"avgChangeRate":0.037069},{"month":5,"riseRate":0.571429,"avgChangeRate":0.025955},{"month":6,"riseRate":0.428571,"avgChangeRate":0.017264},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.00631},{"month":8,"riseRate":0.538462,"avgChangeRate":0.017969},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.008174},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.026814},{"month":11,"riseRate":0.692308,"avgChangeRate":0.066842},{"month":12,"riseRate":0.538462,"avgChangeRate":0.032185}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction